Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 240

1.

Immunovirological outcomes and resistance patterns at 4 years of antiretroviral therapy use in HIV-infected patients in Cambodia.

Pujades-Rodríguez M, Schramm B, Som L, Nerrienet E, Narom P, Chanchhaya N, Ferradini L, Balkan S.

Trop Med Int Health. 2011 Feb;16(2):205-13. doi: 10.1111/j.1365-3156.2010.02689.x. Epub 2010 Nov 19.

2.

Immunovirological and therapeutic follow-up of HIV-1/HIV-2-dually seropositive patients.

Landman R, Damond F, Gerbe J, Brun-Vezinet F, Yeni P, Matheron S.

AIDS. 2009 Jan 28;23(3):426-8. doi: 10.1097/QAD.0b013e328321305a.

PMID:
19114866
3.

Guidelines for using antiretroviral agents among HIV-infected adults and adolescents.

Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK; Panel on Clinical Practices for Treatment of HIV.

Ann Intern Med. 2002 Sep 3;137(5 Pt 2):381-433.

PMID:
12617573
4.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
5.

Short communication: three years follow-up of first-line antiretroviral therapy in cambodia: negative impact of prior antiretroviral treatment.

Ségéral O, Limsreng S, Nouhin J, Hak C, Ngin S, De Lavaissière M, Goujard C, Taburet AM, Nerrienet E, Delfraissy JF, Ouk V, Dulioust A.

AIDS Res Hum Retroviruses. 2011 Jun;27(6):597-603. doi: 10.1089/AID.2010.0125. Epub 2011 Jan 17.

PMID:
21083413
6.

HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time.

Ghosn J, Pellegrin I, Goujard C, Deveau C, Viard JP, Galimand J, Harzic M, Tamalet C, Meyer L, Rouzioux C, Chaix ML; French PRIMO Cohort Study Group (ANRS CO 06).

AIDS. 2006 Jan 9;20(2):159-70.

PMID:
16511408
7.
8.

Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.

Pariente N, Pernas M, de la Rosa R, Gómez-Mariano G, Fernández G, Rubio A, López M, Benito JM, López-Galíndez C, Leal M, Domingo E, Martinez MA, Mas A.

J Med Virol. 2004 Jul;73(3):350-61.

PMID:
15170628
9.

Genotypic resistance and HIV-1 subtype in Brazilian children on dual and triple combination therapy.

Machado ES, Lambert JS, Watson DC, Afonso AO, da Cunha SM, Nogueira SA, Caride E, Oliveira RH, Sill AM, DeVico A, Tanuri A.

J Clin Virol. 2004 May;30(1):24-31.

PMID:
15072750
10.

Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Côte d'Ivoire.

Djomand G, Roels T, Ellerbrock T, Hanson D, Diomande F, Monga B, Maurice C, Nkengasong J, Konan-Koko R, Kadio A, Wiktor S, Lackritz E, Saba J, Chorba T.

AIDS. 2003 Jul;17 Suppl 3:S5-15.

PMID:
14565604
11.

Intermittent antiretroviral therapy in patients with controlled HIV infection.

Marchou B, Tangre P, Charreau I, Izopet J, Girard PM, May T, Ragnaud JM, Aboulker JP, Molina JM; ANRS 106 Study team.

AIDS. 2007 Feb 19;21(4):457-66.

PMID:
17301564
12.

History of viral suppression on combination antiretroviral therapy as a predictor of virological failure after a treatment change.

Reekie J, Mocroft A, Ledergerber B, Beniowski M, Clotet B, van Lunzen J, Chiesi A, Pradier C, Machala L, Lundgren JD; EuroSIDA Study Group.

HIV Med. 2010 Aug;11(7):469-78. doi: 10.1111/j.1468-1293.2009.00816.x. Epub 2010 Feb 22.

13.

Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy.

Hunt PW, Deeks SG, Rodriguez B, Valdez H, Shade SB, Abrams DI, Kitahata MM, Krone M, Neilands TB, Brand RJ, Lederman MM, Martin JN.

AIDS. 2003 Sep 5;17(13):1907-15.

PMID:
12960823
14.

Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment.

Nuesch R, Ananworanich J, Sirivichayakul S, Ubolyam S, Siangphoe U, Hill A, Cooper D, Lange J, Phanuphak P, Ruxrungtham K.

Clin Infect Dis. 2005 Mar 1;40(5):728-34. Epub 2005 Feb 4.

PMID:
15714420
15.

Effective treatment of patients in a deep salvage situation with "non-active HAART": experiences with the expert advice system RADATA.

Lorenzen T, Walther I, Stoehr A, Salzberger B, Plettenberg A; Radata Study Group.

Infection. 2009 Dec;37(6):528-33. doi: 10.1007/s15010-009-9022-6. Epub 2009 Oct 13.

PMID:
19826762
16.

Long-distance interactive expert advice in highly treatment-experienced HIV-infected patients.

Llibre JM, Domingo P, del Pozo MA, Miralles C, Galindo MJ, Viciana I, Moreno S, Schapiro JM, Clotet B.

J Antimicrob Chemother. 2008 Jan;61(1):206-9. Epub 2007 Nov 13.

PMID:
17999972
17.

[Structured therapeutic interruption in patients infected with HIV-1 experiencing a block in their antiretroviral treatment: preliminary results].

Rey D, Schmitt MP, Hess-Kempf G, Krantz V, Partisani M, Bernard-Henry C, Lang JM.

Pathol Biol (Paris). 2001 Sep;49(7):559-66. French.

PMID:
11642019
18.

[Therapeutic effect and safety evaluation on 6-year highly active antiretroviral therapy for Chinese HIV-1 infected patients].

Zhou H, Zheng Y, He Y, Gong G, Chen Z, Liu M, Yin W, Liu C.

Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2009 Aug;34(8):731-7. Chinese.

19.

Net benefits of resistance testing directed therapy compared with standard of care in HIV-infected patients with virological failure: A meta-analysis.

Ena J, Ruiz de Apodaca RF, Amador C, Benito C, Pasquau F.

Enferm Infecc Microbiol Clin. 2006 Apr;24(4):232-7.

PMID:
16725082
20.

Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.

Rodes B, García F, Gutierrez C, Martinez-Picado J, Aguilera A, Saumoy M, Vallejo A, Domingo P, Dalmau D, Ribas MA, Blanco JL, Pedreira J, Perez-Elias MJ, Leal M, de Mendoza C, Soriano V; Red de Investigación en SIDA.

J Med Virol. 2005 Sep;77(1):23-8.

PMID:
16032728

Supplemental Content

Support Center